While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks. More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
SNY
China’s Diabetes Epidemic Boosts Big Pharma
The world's largest population of diabetics is growing alarmingly, and combating it raises the prospects for names like Merck, Novo Nordisk and Sanofi. More
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why. More
Investors Who Own Japanese Stocks About to Get a Surprise
The China-Japan trade relationship in on a rocky road due to the Senkaku/Daiouy Islands dispute, and the problems extend to U.S. investors in Japanese stocks More
Should I Buy Abbott Labs? 3 Pros, 3 Cons
Success in a drug regimen meant to treat hepatitis C is buoying shares of Abbott Laboratories, but has the easy money in ABT shares already been made? More
6 Pharmaceutical Stocks to Buy Now
The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now. More
